Risk Assessment of Death of Tumor-Related PTE by CAR Combined with DD Detection.
C-reactive protein
C-reactive protein/albumin ratio
albumin
neutrophil/lymphocyte
plasma D-dimer
pulmonary thromboembolism
risk assessment of death
Journal
Vascular health and risk management
ISSN: 1178-2048
Titre abrégé: Vasc Health Risk Manag
Pays: New Zealand
ID NLM: 101273479
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
03
2022
accepted:
01
06
2022
entrez:
30
6
2022
pubmed:
1
7
2022
medline:
2
7
2022
Statut:
epublish
Résumé
To investigate the risk of death in patients with tumor-related PTE (pulmonary thromboembolism) detected by CAR (C-reactive protein/albumin ratio) combined with DD (D-dimer). The peripheral hematology and coagulation-related indexes of 109 patients with tumor-related PTE diagnosed by PTCA were retrospectively analyzed, and the differences in relationship indexes between tumor-related PTE patients with good prognosis and poor prognosis were compared and analyzed. The receiver operating characteristic curve (ROC) was used to analyze the risk of death in patients with tumor-related PTE by CAR and DD. ① The values of CAR and DD in the poor prognosis group were 3.90 ± 2.69 and 21.25 ± 21.20, respectively, which were significantly higher than those in the good prognosis group (1.66 ± 1.77, 9.53 ± 3.57) ( CAR and DD were highly expressed in patients with poor prognosis of tumor-related PTE. CAR combined with DD detection is helpful to improve the correct assessment of the risk of death in patients with tumor-related PTE.
Identifiants
pubmed: 35769599
doi: 10.2147/VHRM.S365323
pii: 365323
pmc: PMC9234313
doi:
Substances chimiques
Fibrin Fibrinogen Degradation Products
0
fibrin fragment D
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
445-451Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022 Li et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests in this work.
Références
Clin Respir J. 2019 Mar;13(3):174-183
pubmed: 30712325
Folia Med Cracov. 2018;58(4):57-74
pubmed: 30745602
Blood. 2009 Mar 26;113(13):2878-87
pubmed: 19008457
J Thromb Haemost. 2007 Mar;5(3):632-4
pubmed: 17319909
Semin Oncol. 2019 Feb;46(1):48-56
pubmed: 30655021
Ann Surg Oncol. 2015 Mar;22(3):803-10
pubmed: 25190127
Lancet. 1999 Apr 24;353(9162):1386-9
pubmed: 10227218
PLoS One. 2016 Jun 03;11(6):e0156511
pubmed: 27258044
Clin Respir J. 2021 Jan;15(1):65-73
pubmed: 32931143
J Thromb Thrombolysis. 2019 Jul;48(1):174-179
pubmed: 31041652
Hematol Oncol. 2016 Dec;34(4):184-192
pubmed: 26052918
J Oncol Pharm Pract. 2007 Jun;13(2):85-97
pubmed: 17873108
Int J Gen Med. 2021 Dec 01;14:9219-9225
pubmed: 34880661
Int J Gen Med. 2021 Oct 27;14:7181-7185
pubmed: 34737613
Thromb Res. 2003 Jun 1;110(4):167-72
pubmed: 14512077
Cancer. 2007 Nov 15;110(10):2339-46
pubmed: 17918266
Sci Rep. 2015 Jun 18;5:10481
pubmed: 26084991
Eur Arch Otorhinolaryngol. 2016 Oct;273(10):3443
pubmed: 26758465
Mol Imaging Radionucl Ther. 2020 Oct 19;29(3):112-117
pubmed: 33094574
Hematology. 2020 Dec;25(1):134-138
pubmed: 32153255